No Data
MediciNova Announces That The National Institutes Of Health Neurological Disorders And Stroke Has Awarded $22M For An Intermediate Size Expanded Access Protocol To Evaluate The Efficacy Of MN-166 In Amyotrophic Lateral Sclerosis
Express News | MediciNova Inc - Nih Awards $22 Million for Eap to Evaluate Mn-166 in ALS
Express News | Medicinova to Support Nih-Funded Expanded Access Clinical Trial to Evaluate Mn166 (Ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
Express News | Medicinova Announces Acceptance of Abstract Regarding Mn-166 (Ibudilast) in Combat-ALS Clinical Trial for Presentation at the 2024 Annual Neals (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
MediciNova Shares Are Trading Higher After the Company Announced That It Received a Notice of Allowance From the U.S. Patent and Trademark Office for a Pending Patent Application, Which Covers MN-166 for Post-COVID Conditions.
Sector Update: Health Care Stocks Softer in Afternoon Trading